View ValuationRedcare Pharmacy 将来の成長Future 基準チェック /46Redcare Pharmacy利益と収益がそれぞれ年間55.4%と10.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.5% 55.9%なると予測されています。主要情報55.4%収益成長率55.92%EPS成長率Consumer Retailing 収益成長10.0%収益成長率10.5%将来の株主資本利益率12.46%アナリストカバレッジGood最終更新日08 May 2026今後の成長に関する最新情報Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.お知らせ • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.お知らせ • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.お知らせ • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026お知らせ • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.お知らせ • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.お知らせ • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.お知らせ • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.お知らせ • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025お知らせ • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.お知らせ • Mar 11Redcare Pharmacy NV to Report Q1, 2025 Results on May 06, 2025Redcare Pharmacy NV announced that they will report Q1, 2025 results on May 06, 2025お知らせ • Jan 09Redcare Pharmacy NV to Report Fiscal Year 2024 Final Results on Mar 11, 2025Redcare Pharmacy NV announced that they will report fiscal year 2024 final results on Mar 11, 2025Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • Nov 10Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €574.5m (up 21% from 3Q 2023). Net loss: €6.91m (down 183% from profit in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe.Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.お知らせ • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.Reported Earnings • Jul 31Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €560.7m (up 34% from 2Q 2023). Net loss: €4.27m (loss narrowed 6.4% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Europe.お知らせ • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding).Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €560.2m (up 51% from 1Q 2023). Net loss: €7.81m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe.お知らせ • Mar 07Redcare Pharmacy NV Announces Management DeparturesThe Supervisory Board of Redcare Pharmacy NV agreed to the early departure request of the Managing Board members Stephan Weber (CCO) and Marc Fischer (CIO) at the Annual General Meeting on 17 April 2024. This decision comes at an ideal time to transition leadership responsibilities approximately one year before the end of their regular terms of office. This succession plan had been carefully developed and is the result of an extensive evaluation and selection process. Both Stephan Weber and Marc Fischer have agreed with the Supervisory Board to serve Redcare Pharmacy in an advisory capacity until October 2026, provided the relevant agenda item is approved by the Annual General Meeting.New Risk • Mar 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.お知らせ • Mar 06+ 2 more updatesRedcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024Redcare Pharmacy NV announced that they will report Q3, 2024 results on Nov 05, 2024Reported Earnings • Mar 06Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: €0.73 loss per share (improved from €4.32 loss in FY 2022). Revenue: €1.80b (up 49% from FY 2022). Net loss: €12.0m (loss narrowed 85% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 05Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024, at 10:00 Central European Standard Time. Agenda: To consider directorate changes.Price Target Changed • Jan 09Price target increased by 7.6% to €142Up from €132, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €140. Stock is up 144% over the past year. The company is forecast to post a net loss per share of €0.86 next year compared to a net loss per share of €4.32 last year.Breakeven Date Change • Nov 10Forecast breakeven date moved forward to 2024The 11 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 76% to 2023. The company is expected to make a profit of €229.6k in 2024. Average annual earnings growth of 64% is required to achieve expected profit on schedule.Reported Earnings • Oct 31Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €475.5m (up 67% from 3Q 2022). Net income: €8.32m (up €28.4m from 3Q 2022). Profit margin: 1.7% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe.Recent Insider Transactions • Aug 11CFO & Member of Management Board recently sold €1.0m worth of stockOn the 7th of August, Jasper F. Eenhorst sold around 9k shares on-market at roughly €112 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jasper F. has been a net seller over the last 12 months, reducing personal holdings by €992k.New Risk • Aug 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Significant insider selling over the past 3 months (€454k sold).Reported Earnings • Aug 02Second quarter 2023 earnings released: €0.24 loss per share (vs €1.37 loss in 2Q 2022)Second quarter 2023 results: €0.24 loss per share (improved from €1.37 loss in 2Q 2022). Revenue: €419.9m (up 46% from 2Q 2022). Net loss: €4.56m (loss narrowed 82% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.New Risk • Jun 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €65m Forecast net loss in 2 years: €3.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.3m net loss in 2 years). Significant insider selling over the past 3 months (€785k sold).Price Target Changed • Jun 08Price target increased by 8.1% to €101Up from €93.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €96.06. Stock is up 7.1% over the past year. The company is forecast to post a net loss per share of €1.87 next year compared to a net loss per share of €4.32 last year.Price Target Changed • May 23Price target increased by 7.5% to €99.08Up from €92.17, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €97.98. Stock is up 15% over the past year. The company is forecast to post a net loss per share of €2.97 next year compared to a net loss per share of €4.32 last year.Recent Insider Transactions • May 12Co-Founder recently sold €454k worth of stockOn the 5th of May, Marc Fischer sold around 5k shares on-market at roughly €90.80 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.Breakeven Date Change • May 05Forecast to breakeven in 2025The 9 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €15.8m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: €0.56 loss per share. Revenue: €372.1m (up 22% from 1Q 2022). Net loss: €10.2m (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe.Breakeven Date Change • Apr 11Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.44m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Recent Insider Transactions • Apr 05COO & Member of the Managing Board recently sold €331k worth of stockOn the 30th of March, Theresa Holler sold around 4k shares on-market at roughly €78.85 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.Reported Earnings • Mar 09Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: €4.32 loss per share (further deteriorated from €4.15 loss in FY 2021). Revenue: €1.20b (up 14% from FY 2021). Net loss: €77.6m (loss widened 4.7% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Breakeven Date Change • Mar 08No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €26.3m in 2025. New consensus forecast suggests the company will make a loss of €377.1k in 2025.Recent Insider Transactions • Jan 31COO & Member of the Managing Board recently sold €149k worth of stockOn the 24th of January, Theresa Holler sold around 2k shares on-market at roughly €64.72 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Theresa has been a net seller over the last 12 months, reducing personal holdings by €260k.Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €66.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 78% in the next 2 years.Price Target Changed • Jan 05Price target decreased to €84.43Down from €92.00, the current price target is an average from 14 analysts. New target price is 63% above last closing price of €51.68. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €4.02 next year compared to a net loss per share of €4.15 last year.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €26.3m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 22Chairman of the Managing Board & CEO recently bought €85k worth of stockOn the 16th of December, Stefan Feltens bought around 2k shares on-market at roughly €42.58 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.お知らせ • Dec 20+ 3 more updatesShop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023Shop Apotheke Europe N.V. announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Mar 07, 2023Price Target Changed • Nov 10Price target decreased to €91.64Down from €98.79, the current price target is an average from 14 analysts. New target price is 106% above last closing price of €44.43. Stock is down 70% over the past year. The company is forecast to post a net loss per share of €3.69 next year compared to a net loss per share of €4.15 last year.Reported Earnings • Nov 03Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €284.5m (up 20% from 3Q 2021). Net loss: €20.1m (loss widened 37% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe.Price Target Changed • Oct 27Price target decreased to €98.79Down from €115, the current price target is an average from 14 analysts. New target price is 126% above last closing price of €43.64. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €3.72 next year compared to a net loss per share of €4.15 last year.Recent Insider Transactions • Aug 28Co-Founder recently sold €972k worth of stockOn the 23rd of August, Stephan Weber sold around 15k shares on-market at roughly €67.03 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.5m. Stephan has been a seller over the last 12 months, reducing personal holdings by €1.9m.Breakeven Date Change • Aug 06No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.03m in 2024. New consensus forecast suggests the company will make a loss of €2.04m in 2024.Reported Earnings • Aug 05Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €287.2m (up 15% from 2Q 2021). Net loss: €24.8m (loss widened 122% from 2Q 2021). Over the next year, revenue is forecast to grow 26%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.Recent Insider Transactions • Jun 19COO & Member of the Managing Board recently sold €1.5m worth of stockOn the 15th of June, Theresa Holler sold around 18k shares on-market at roughly €82.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months.Recent Insider Transactions • Jun 10Co-Founder recently sold €953k worth of stockOn the 2nd of June, Stephan Weber sold around 10k shares on-market at roughly €95.33 per share. This was the largest sale by an insider in the last 3 months. This was Stephan's only on-market trade for the last 12 months.Breakeven Date Change • May 09No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.Reported Earnings • May 08First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €304.8m (up 7.3% from 1Q 2021). Net loss: €22.9m (loss widened 296% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 7.6% growth forecast for the industry in Germany.Breakeven Date Change • Apr 22No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.93m in 2024.Breakeven Date Change • Apr 09No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.14m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.Recent Insider Transactions • Mar 10Co-Founder recently sold €916k worth of stockOn the 4th of March, Marc Fischer sold around 13k shares on-market at roughly €73.30 per share. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2024The 13 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 99% per year to 2023. The company is expected to make a profit of €12.5m in 2024. Average annual earnings growth of 85% is required to achieve expected profit on schedule.Reported Earnings • Mar 04Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €1.06b (up 9.5% from FY 2020). Net loss: €74.2m (loss widened 342% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 8.3% growth forecast for the retail industry in Germany.Price Target Changed • Mar 04Price target decreased to €150Down from €163, the current price target is an average from 13 analysts. New target price is 93% above last closing price of €77.95. Stock is down 56% over the past year.Breakeven Date Change • Mar 03Forecast breakeven date pushed back to 2024The 6 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of €33.7m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Reported Earnings • Nov 03Third quarter 2021 earnings releasedThe company reported a poor third quarter result with increased losses and weaker control over costs, although revenues were flat. Third quarter 2021 results: Revenue: €237.9m (flat on 3Q 2020). Net loss: €14.7m (loss widened 240% from 3Q 2020).Breakeven Date Change • Aug 10Forecast breakeven pushed back to 2023The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 68% per year to 2022. The company is expected to make a profit of €24.7m in 2023. Average annual earnings growth of 121% is required to achieve expected profit on schedule.Reported Earnings • Aug 08Second quarter 2021 earnings releasedThe company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €250.4m (up 7.6% from 2Q 2020). Net loss: €11.2m (loss widened €11.0m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Jul 15Price target decreased to €202Down from €221, the current price target is an average from 9 analysts. New target price is 52% above last closing price of €133. Stock is up 9.6% over the past year.Breakeven Date Change • Jun 16Forecast breakeven pushed back to 2022The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 98% to 2021. The company is expected to make a profit of €17.4m in 2022. Average annual earnings growth of 102% is required to achieve expected profit on schedule.Reported Earnings • May 08First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: €284.1m (up 22% from 1Q 2020). Net loss: €5.79m (loss widened 17% from 1Q 2020).Executive Departure • Apr 30Chairman of the Supervisory Board Jan Pyttel has left the companyOn the 21st of April, Jan Pyttel's tenure in the role of Chairman of the Supervisory Board ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months.Recent Insider Transactions • Mar 14Chairman of the Managing Board & CEO recently bought €96k worth of stockOn the 8th of March, Stefan Feltens bought around 550 shares on-market at roughly €175 per share. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.Reported Earnings • Mar 05Full year 2020 earnings released: €1.17 loss per share (vs €2.78 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €968.1m (up 38% from FY 2019). Net loss: €16.8m (loss narrowed 54% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Mar 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 0.2%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 23%, compared to a 54% growth forecast for the Online Retail industry in Germany.Is New 90 Day High Low • Feb 03New 90-day high: €210The company is up 29% from its price of €162 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 25% over the same period.Is New 90 Day High Low • Jan 13New 90-day high: €165The company is up 4.0% from its price of €159 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 21% over the same period.Analyst Estimate Surprise Post Earnings • Nov 20Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 26%, compared to a 46% growth forecast for the Online Retail industry in Germany.Analyst Estimate Surprise Post Earnings • Nov 09Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 25%, compared to a 47% growth forecast for the Online Retail industry in Germany.Is New 90 Day High Low • Nov 08New 90-day high: €164The company is up 20% from its price of €137 on 10 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.業績と収益の成長予測DB:RDC - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20284,0944969127712/31/20273,705133889812/31/20263,339-1925983/31/20263,073-37-10217N/A12/31/20252,941-38-8831N/A9/30/20252,821-35-6233N/A6/30/20252,676-35-3644N/A3/31/20252,528-48-1538N/A12/31/20242,371-45-2022N/A9/30/20242,227-25-1131N/A6/30/20242,128-9-833N/A3/31/20241,987-10038N/A12/31/20231,799-122361N/A9/30/20231,595-16-240N/A6/30/20231,404-45-1333N/A3/31/20231,272-65-59-9N/A12/31/20221,204-78-83-29N/A9/30/20221,165-110-68-16N/A6/30/20221,118-105-481N/A3/31/20221,081-91-406N/A12/31/20211,060-74-3212N/A9/30/20211,037-39-1435N/A6/30/20211,038-29-2827N/A3/31/20211,020-18-1735N/A12/31/2020968-17-3618N/A9/30/2020895-15-56-19N/A6/30/2020827-20-43-19N/A3/31/2020758-27-38-16N/A12/31/2019701-36N/A-31N/A9/30/2019660-41N/A-11N/A6/30/2019621-40N/A-10N/A3/31/2019584-40N/A-26N/A12/31/2018540-34N/A-15N/A9/30/2018481-31N/A-31N/A6/30/2018415-28N/A-24N/A3/31/2018351-24N/A-17N/A12/31/2017284-21N/A-23N/A9/30/2017244-22N/A-11N/A6/30/2017222-20N/A-16N/A3/31/2017200-20N/A-14N/A12/31/2016177-18N/A-17N/A9/30/2016159-13N/A-5N/A6/30/2016147-13N/A-5N/A3/31/2016136-12N/A-7N/A12/31/2015126-11N/A-9N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RDCは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。収益対市場: RDC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: RDC今後 3 年以内に収益を上げることが予想されます。収益対市場: RDCの収益 ( 10.5% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: RDCの収益 ( 10.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RDCの 自己資本利益率 は、3年後には低くなると予測されています ( 12.5 %)。成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:53終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Redcare Pharmacy NV 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Gerhard SchwarzBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchSarah RobertsBarclays21 その他のアナリストを表示
Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.
お知らせ • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.
Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
お知らせ • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.
Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.
お知らせ • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026
お知らせ • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.
お知らせ • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026
Price Target Changed • Jan 07Price target decreased by 7.5% to €140Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year.
お知らせ • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.
お知らせ • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.
お知らせ • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025
お知らせ • Mar 13Redcare Pharmacy NV Provides Earnings Guidance for 2025Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%.
お知らせ • Mar 11Redcare Pharmacy NV to Report Q1, 2025 Results on May 06, 2025Redcare Pharmacy NV announced that they will report Q1, 2025 results on May 06, 2025
お知らせ • Jan 09Redcare Pharmacy NV to Report Fiscal Year 2024 Final Results on Mar 11, 2025Redcare Pharmacy NV announced that they will report fiscal year 2024 final results on Mar 11, 2025
Breakeven Date Change • Dec 30Forecast breakeven date pushed back to 2026The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • Nov 10Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €574.5m (up 21% from 3Q 2023). Net loss: €6.91m (down 183% from profit in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe.
Breakeven Date Change • Oct 28Forecast to breakeven in 2025The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
お知らせ • Oct 04Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion.
Reported Earnings • Jul 31Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €560.7m (up 34% from 2Q 2023). Net loss: €4.27m (loss narrowed 6.4% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Europe.
お知らせ • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.
New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding).
Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €560.2m (up 51% from 1Q 2023). Net loss: €7.81m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe.
お知らせ • Mar 07Redcare Pharmacy NV Announces Management DeparturesThe Supervisory Board of Redcare Pharmacy NV agreed to the early departure request of the Managing Board members Stephan Weber (CCO) and Marc Fischer (CIO) at the Annual General Meeting on 17 April 2024. This decision comes at an ideal time to transition leadership responsibilities approximately one year before the end of their regular terms of office. This succession plan had been carefully developed and is the result of an extensive evaluation and selection process. Both Stephan Weber and Marc Fischer have agreed with the Supervisory Board to serve Redcare Pharmacy in an advisory capacity until October 2026, provided the relevant agenda item is approved by the Annual General Meeting.
New Risk • Mar 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Breakeven Date Change • Mar 07Forecast breakeven date moved forward to 2024The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Mar 06+ 2 more updatesRedcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024Redcare Pharmacy NV announced that they will report Q3, 2024 results on Nov 05, 2024
Reported Earnings • Mar 06Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: €0.73 loss per share (improved from €4.32 loss in FY 2022). Revenue: €1.80b (up 49% from FY 2022). Net loss: €12.0m (loss narrowed 85% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 05Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024, at 10:00 Central European Standard Time. Agenda: To consider directorate changes.
Price Target Changed • Jan 09Price target increased by 7.6% to €142Up from €132, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €140. Stock is up 144% over the past year. The company is forecast to post a net loss per share of €0.86 next year compared to a net loss per share of €4.32 last year.
Breakeven Date Change • Nov 10Forecast breakeven date moved forward to 2024The 11 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 76% to 2023. The company is expected to make a profit of €229.6k in 2024. Average annual earnings growth of 64% is required to achieve expected profit on schedule.
Reported Earnings • Oct 31Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €475.5m (up 67% from 3Q 2022). Net income: €8.32m (up €28.4m from 3Q 2022). Profit margin: 1.7% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe.
Recent Insider Transactions • Aug 11CFO & Member of Management Board recently sold €1.0m worth of stockOn the 7th of August, Jasper F. Eenhorst sold around 9k shares on-market at roughly €112 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jasper F. has been a net seller over the last 12 months, reducing personal holdings by €992k.
New Risk • Aug 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Significant insider selling over the past 3 months (€454k sold).
Reported Earnings • Aug 02Second quarter 2023 earnings released: €0.24 loss per share (vs €1.37 loss in 2Q 2022)Second quarter 2023 results: €0.24 loss per share (improved from €1.37 loss in 2Q 2022). Revenue: €419.9m (up 46% from 2Q 2022). Net loss: €4.56m (loss narrowed 82% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
New Risk • Jun 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €65m Forecast net loss in 2 years: €3.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.3m net loss in 2 years). Significant insider selling over the past 3 months (€785k sold).
Price Target Changed • Jun 08Price target increased by 8.1% to €101Up from €93.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €96.06. Stock is up 7.1% over the past year. The company is forecast to post a net loss per share of €1.87 next year compared to a net loss per share of €4.32 last year.
Price Target Changed • May 23Price target increased by 7.5% to €99.08Up from €92.17, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €97.98. Stock is up 15% over the past year. The company is forecast to post a net loss per share of €2.97 next year compared to a net loss per share of €4.32 last year.
Recent Insider Transactions • May 12Co-Founder recently sold €454k worth of stockOn the 5th of May, Marc Fischer sold around 5k shares on-market at roughly €90.80 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.
Breakeven Date Change • May 05Forecast to breakeven in 2025The 9 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €15.8m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: €0.56 loss per share. Revenue: €372.1m (up 22% from 1Q 2022). Net loss: €10.2m (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe.
Breakeven Date Change • Apr 11Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.44m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Recent Insider Transactions • Apr 05COO & Member of the Managing Board recently sold €331k worth of stockOn the 30th of March, Theresa Holler sold around 4k shares on-market at roughly €78.85 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.
Reported Earnings • Mar 09Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: €4.32 loss per share (further deteriorated from €4.15 loss in FY 2021). Revenue: €1.20b (up 14% from FY 2021). Net loss: €77.6m (loss widened 4.7% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Breakeven Date Change • Mar 08No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €26.3m in 2025. New consensus forecast suggests the company will make a loss of €377.1k in 2025.
Recent Insider Transactions • Jan 31COO & Member of the Managing Board recently sold €149k worth of stockOn the 24th of January, Theresa Holler sold around 2k shares on-market at roughly €64.72 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Theresa has been a net seller over the last 12 months, reducing personal holdings by €260k.
Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €66.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 78% in the next 2 years.
Price Target Changed • Jan 05Price target decreased to €84.43Down from €92.00, the current price target is an average from 14 analysts. New target price is 63% above last closing price of €51.68. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €4.02 next year compared to a net loss per share of €4.15 last year.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €26.3m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 22Chairman of the Managing Board & CEO recently bought €85k worth of stockOn the 16th of December, Stefan Feltens bought around 2k shares on-market at roughly €42.58 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.
お知らせ • Dec 20+ 3 more updatesShop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023Shop Apotheke Europe N.V. announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Mar 07, 2023
Price Target Changed • Nov 10Price target decreased to €91.64Down from €98.79, the current price target is an average from 14 analysts. New target price is 106% above last closing price of €44.43. Stock is down 70% over the past year. The company is forecast to post a net loss per share of €3.69 next year compared to a net loss per share of €4.15 last year.
Reported Earnings • Nov 03Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €284.5m (up 20% from 3Q 2021). Net loss: €20.1m (loss widened 37% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe.
Price Target Changed • Oct 27Price target decreased to €98.79Down from €115, the current price target is an average from 14 analysts. New target price is 126% above last closing price of €43.64. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €3.72 next year compared to a net loss per share of €4.15 last year.
Recent Insider Transactions • Aug 28Co-Founder recently sold €972k worth of stockOn the 23rd of August, Stephan Weber sold around 15k shares on-market at roughly €67.03 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.5m. Stephan has been a seller over the last 12 months, reducing personal holdings by €1.9m.
Breakeven Date Change • Aug 06No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.03m in 2024. New consensus forecast suggests the company will make a loss of €2.04m in 2024.
Reported Earnings • Aug 05Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €287.2m (up 15% from 2Q 2021). Net loss: €24.8m (loss widened 122% from 2Q 2021). Over the next year, revenue is forecast to grow 26%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Jun 19COO & Member of the Managing Board recently sold €1.5m worth of stockOn the 15th of June, Theresa Holler sold around 18k shares on-market at roughly €82.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 10Co-Founder recently sold €953k worth of stockOn the 2nd of June, Stephan Weber sold around 10k shares on-market at roughly €95.33 per share. This was the largest sale by an insider in the last 3 months. This was Stephan's only on-market trade for the last 12 months.
Breakeven Date Change • May 09No longer forecast to breakevenThe 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.
Reported Earnings • May 08First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €304.8m (up 7.3% from 1Q 2021). Net loss: €22.9m (loss widened 296% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 7.6% growth forecast for the industry in Germany.
Breakeven Date Change • Apr 22No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.93m in 2024.
Breakeven Date Change • Apr 09No longer forecast to breakevenThe 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.14m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024.
Recent Insider Transactions • Mar 10Co-Founder recently sold €916k worth of stockOn the 4th of March, Marc Fischer sold around 13k shares on-market at roughly €73.30 per share. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months.
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2024The 13 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 99% per year to 2023. The company is expected to make a profit of €12.5m in 2024. Average annual earnings growth of 85% is required to achieve expected profit on schedule.
Reported Earnings • Mar 04Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €1.06b (up 9.5% from FY 2020). Net loss: €74.2m (loss widened 342% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 8.3% growth forecast for the retail industry in Germany.
Price Target Changed • Mar 04Price target decreased to €150Down from €163, the current price target is an average from 13 analysts. New target price is 93% above last closing price of €77.95. Stock is down 56% over the past year.
Breakeven Date Change • Mar 03Forecast breakeven date pushed back to 2024The 6 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of €33.7m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Reported Earnings • Nov 03Third quarter 2021 earnings releasedThe company reported a poor third quarter result with increased losses and weaker control over costs, although revenues were flat. Third quarter 2021 results: Revenue: €237.9m (flat on 3Q 2020). Net loss: €14.7m (loss widened 240% from 3Q 2020).
Breakeven Date Change • Aug 10Forecast breakeven pushed back to 2023The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 68% per year to 2022. The company is expected to make a profit of €24.7m in 2023. Average annual earnings growth of 121% is required to achieve expected profit on schedule.
Reported Earnings • Aug 08Second quarter 2021 earnings releasedThe company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €250.4m (up 7.6% from 2Q 2020). Net loss: €11.2m (loss widened €11.0m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Jul 15Price target decreased to €202Down from €221, the current price target is an average from 9 analysts. New target price is 52% above last closing price of €133. Stock is up 9.6% over the past year.
Breakeven Date Change • Jun 16Forecast breakeven pushed back to 2022The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 98% to 2021. The company is expected to make a profit of €17.4m in 2022. Average annual earnings growth of 102% is required to achieve expected profit on schedule.
Reported Earnings • May 08First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: €284.1m (up 22% from 1Q 2020). Net loss: €5.79m (loss widened 17% from 1Q 2020).
Executive Departure • Apr 30Chairman of the Supervisory Board Jan Pyttel has left the companyOn the 21st of April, Jan Pyttel's tenure in the role of Chairman of the Supervisory Board ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months.
Recent Insider Transactions • Mar 14Chairman of the Managing Board & CEO recently bought €96k worth of stockOn the 8th of March, Stefan Feltens bought around 550 shares on-market at roughly €175 per share. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.
Reported Earnings • Mar 05Full year 2020 earnings released: €1.17 loss per share (vs €2.78 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €968.1m (up 38% from FY 2019). Net loss: €16.8m (loss narrowed 54% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Mar 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 0.2%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 23%, compared to a 54% growth forecast for the Online Retail industry in Germany.
Is New 90 Day High Low • Feb 03New 90-day high: €210The company is up 29% from its price of €162 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 25% over the same period.
Is New 90 Day High Low • Jan 13New 90-day high: €165The company is up 4.0% from its price of €159 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 21% over the same period.
Analyst Estimate Surprise Post Earnings • Nov 20Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 26%, compared to a 46% growth forecast for the Online Retail industry in Germany.
Analyst Estimate Surprise Post Earnings • Nov 09Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 25%, compared to a 47% growth forecast for the Online Retail industry in Germany.
Is New 90 Day High Low • Nov 08New 90-day high: €164The company is up 20% from its price of €137 on 10 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.